Evidence map›Paper›PMID 36314021›Full record

ArticleFrontiers in medicine2022

Assessment of

Emilie Thivat, Marion Chanchou, Sylvain Mathieu, Sophie Levesque, Tommy Billoux, Philippe Auzeloux, Nicolas Sas, Ioana Molnar, Elodie Jouberton, Jacques Rouanet and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04481230 (Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04481230 early_phase1completednot on this map

Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer: Phase I Clinical Trial

TypeinterventionalSponsorCentre Jean PerrinRan2020 to 2022Enrolled6ConditionsOsteoarthritis, Knee, Breast CancerArms99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg, 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg, 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [EJNMMI research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Emilie ThivatInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Marion ChanchouInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Sylvain MathieuService de Rhumatologie, Centre Hospitalier Universitaire (CHU) Gabriel Montpied, Université Clermont-Auvergne, Clermont-Ferrand, France.
Sophie LevesqueInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Tommy BillouxInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Philippe AuzelouxInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Nicolas SasInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Ioana MolnarInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Elodie JoubertonInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Jacques RouanetInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Giovanna FoisLaboratoire de Physique de Clermont, UMR6533, Centre National de la Recherche Scientifique (CNRS)/Institut National de Physique Nucléaire et de Physique des Particules (IN2P3), Université Clermont Auvergne, Clermont-Ferrand, France.
Lydia MaigneLaboratoire de Physique de Clermont, UMR6533, Centre National de la Recherche Scientifique (CNRS)/Institut National de Physique Nucléaire et de Physique des Particules (IN2P3), Université Clermont Auvergne, Clermont-Ferrand, France.
Marie-Josephe GalmierInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Frédérique Penault-LlorcaInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Elisabeth Miot-NoiraultInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Xavier DurandoInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.
Florent CachinInstitut National de la Santé et de la Recherche Médicale (INSERM) U1240 Imagerie Moléculaire et Stratégies Theranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: As the clinical development of this radiotracer would be oriented toward the functional imaging of joint pathologies, we have chosen to include patients with healthy joints (unilateral osteoarthritis of the knee or breast cancer with indication of AI treatment). This phase I study will be an open-label, multicenter, dose-escalation trial of a radiopharmaceutical orientation to determine the recommended level of activity of Discussion: This first in-human phase I trial will be proof-of-concept of the relevance of Trial registration number: Clinicaltrials.gov: NCT04481230. Identifier in French National Agency for the Safety of Medicines and Health Products (ANSM): N°EudraCT 2020-000495-37.

Indexed as

cartilagephase Iproteoglycan targetingradiopharmaceutical-diagnostic useSPECT imaging

Identifiers

PMID36314021
PMCPMC9596979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.